ACI
RIGL icon

AMP Capital Investors’s Rigel Pharmaceuticals RIGL Stock Holding History

AMP Capital Investors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-7,660
Closed -$175K – 1314
2020
Q3 		$175K Buy
+7,660
New +$188K ﹤0.01% 1175

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

AMP Capital Investors's RIGL Position: Q4 2020 in Review

AMP Capital Investors sold out of Rigel Pharmaceuticals (RIGL) in Q4 2020, closing a stake of 7,660 shares — an estimated $175K sold.

AMP Capital Investors first reported a position in RIGL in Q3 2020 and held it in 1 quarter. The position peaked at $175K in Q3 2020. 149 funds tracked by Wall St. Rank hold RIGL as of Q4 2020.

  • AMP Capital Investors reported no remaining Rigel Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • AMP Capital Investors sold 7,660 Rigel Pharmaceuticals shares in Q4 2020, an estimated $175K.
  • AMP Capital Investors first reported a position in Rigel Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • AMP Capital Investors's Rigel Pharmaceuticals position peaked at $175K in Q3 2020.
  • 149 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2020.

Based on AMP Capital Investors's 13F filing for Q4 2020, filed 12 Feb 2021.